• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » General » Electromedical Technologies 2019 Highlights and Outlook for 2020

Electromedical Technologies 2019 Highlights and Outlook for 2020

PublicWire by PublicWire
January 21, 2020
in General, Medical
4 min read
61
0

Scottsdale, AZ – January 13, 2020 – Electromedical Technologies Inc. (OTC: ELCQ) (the “Company), the developer and manufacturer of WellnessPro Plus™ therapeutic medical device, is pleased to provide this corporate update summarizing its business to date, and its goals for 2020.

The Company develops and manufactures proprietary medical devices targeting physical pain relief. The Company’s flagship product is the WellnessPro Plus™, developed in 2007. The WellnessPro Plus™ is a portable device designed to deliver localized pain relief, supplied by its distribution of calibrated electrical energy pulses.

The Company’s mission is to develop, market and raise awareness of using electronic pulse therapies as a possible effective replacement or possible complement to current drug therapies targeting pain relief.

The Company’s proprietary technology in the WellnessPro Plus™ is based on its unique energy delivery system called DeepPulse™.  DeepPulse™ delivers a low voltage current to treat localized pain, and the Company believes that it provides longer lasting and more effective pain relief than many drugs and other products on the market.

The WellnessPro Plus™ received FDA clearance on July 6, 2007, as a Class II Medical Device, pursuant to the Company’s FDA clearance granted under section 510(K). The intended use of the WellnessPro Plus™  is for the treatment chronic intractable and acute pain, and as an adjunctive treatment for post-surgical and post-traumatic acute pain. The WellnessPro Plus™ is also qualified to be sold and used in Mexico.

The WellnessPro Plus™ was found to meet device safety standards for Radiated Emissions, Electrostatic Discharge, Radiated Immunity and device safety.

Today, many patients use the WellnessPro Plus™ in a variety of settings by healthcare professionals, athletes, coaches and others.

Commenting on the WellnessPro Plus™, the Company’s President and Principal Executive Officer, Matthew Wolfson, observed:

“A new era and a new category of medicine is emerging in the way we treat chronic pain. By learning to read and correct the electrical signals that travel between the brain and the body’s organs, we believe that a whole new frontier in treating chronic and acute pain will become reality in the not too distant future.  By using energy, frequency and vibration, we want to unlock the body’s natural ability to achieve wellness, better health and a better quality of life. The WellnessPro Plus™ device provides variable and rotating frequencies that we believe triggers endorphin release, which helps to relieve chronic and acute pain without the use of drugs“.

The Company’s 2019 Achievements

The Company completed Regulation A+ Tier II offering; filed 15C-211 with FINRA to commence trading; and listed on the OTC Markets Pink Tier under ticker Symbol “ELCQ.” The Company completed an independent audit of its financials and filed a registration statement with the Securities and Exchange Commission on November 12, 2019, and is working on addressing comments from the Commission, with the goal of becoming a fully reporting company under the Securities Act.

The Company’s Goals for 2020

The Company is actively engaged in research and development efforts on a new device it is calling the “WellnessPro Pod.” The Company envisions this device to provide more portability and features. The Company’s research and development’s goals for the “WellnessPro Pod” will be to expand the therapeutic uses for the Company’s technology, and to determine whether its technology may be helpful in other possible areas of treatment, such as PTSD, insomnia, depression, and anxiety. The Company also intends to pursue research and development to incorporate laser technology into its products that may allow the Company to enter the cosmetic applications market.

The Company also intends to extend its marketing outreach to wellness centers, targeting venues with significant patient traffic. The Company also expects to qualify its products for use in the European Union and Canada, further expanding its available markets.

Disclosure:

The FDA’s issuance of a 510(k) clearance as a Class II Medical Device does not mean that FDA has made a determination that the Company’s device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

Forward-Looking Statements

This news release contains “forward-looking statements,” which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as “anticipate,” “seek,” “intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our Form S1, and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s website at:

https://electromedtech.com/

info@electromedtech.com

Toll free: 888-880-7888

SOURCE:  Electromedical Technologies, Inc.

PublicWire

PublicWire

At PublicWire, we know the vast majority of all investors conduct their due diligence and get their news online in a variety of ways including email, social media, financial websites, text messages, RSS feeds and audio/video podcasts. PublicWire’s financial communications program is uniquely positioned to reach these investors throughout the U.S. and Canada as well as on a global scale.

Related Posts

Regeneron buy back shares from Sanofi
Medical

Regeneron to buy back $5 billion shares from Sanofi

May 25, 2020
132
China Opposed U.S. Audit Plans
General

China Opposed U.S. Audit Plans

May 24, 2020
135
JetBlue gives 100,000 free flights to healthcare workers.
General

JetBlue Announces ‘JetBlue Healthcare Hero’ Program — Giving Away 100,000 Free Flights to Healthcare Workers

May 6, 2020
166
Trans-Pacific flights are most likely to be affected the most with demand declining up to 80% due to the pandemic.
General

American Airlines is looking into canceling up to 60% of its summer schedules as the pandemic continues to push demand down

April 2, 2020
138
Louisiana tops the list of states with the most number of increase in unemployment insurance claims because of the COVID-19 pandemic.
General

Here are the states that suffered the most unemployment due to COVID-19 pandemic

April 2, 2020
151
Kynikos Associates founder warns investors against ‘virus stocks’
General

Kynikos Associates founder warns investors against ‘virus stocks’

April 2, 2020
179
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.